Diffuse large B-cell lymphoma

47 trials 16 recruiting MedDRA PT
47 Registered trials
16 Recruiting
26 Unique sponsors
36 Unique IMPs
32 Commercial trials
Drug classes (ATC)
— ATC code not specified 27
L Oncology (ATC L) 19
N Neurology/Psychiatry (ATC N) 1
H Endocrinology (ATC H) 4
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 9 substances
Antibody-drug conjugate (ADC) 4 substances
Monoclonal antibody 2 substances
Monoclonal antibody (rat) 2 substances
Corticosteroid 2 substances
Antimetabolite 2 substances
IMiD 2 substances
Platinum compound 2 substances
BTK inhibitor 2 substances
CAR-T cell therapy 2 substances
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Alkylating agent 1 substance
Anthracycline 1 substance
Vinca alkaloid 1 substance
Colony-stimulating factor 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Phase III: 14 Phase II: 13 Phase I/II: 3 Phase IV: 1 Phase I: 10 Phase I (Other): 2 Phase I (First in Human): 4

Filter these 47 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 47 trials

Phase III

14 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; EPCORITAMAB; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE
    2023-505277-32-00 16 countries 2023 n=435 Orphan
    Recruiting
  • AbbVie Deutschland GmbH & Co. KG Commercial
    EPCORITAMAB; GEMCITABINE; LENALIDOMIDE; OXALIPLATIN; RITUXIMAB
    2024-510965-41-00 11 countries 2024 n=116 Orphan
    Ended
  • Acerta Pharma B.V. Commercial
    ACALABRUTINIB
    2023-509358-72-00 9 countries 2020 n=221
    Ended
  • ADC Therapeutics S.A. Commercial
    DEXAMETHASONE; LONCASTUXIMAB TESIRINE; RITUXIMAB
    2023-503916-33-00 8 countries 2021 n=228
    Ended
  • Celgene Corp. Commercial
    GOLCADOMIDE; PEGFILGRASTIM
    2023-510178-15-00 17 countries 2024 n=322
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-504028-24-00 7 countries 2023 n=403
    Ended
  • F. Hoffmann-La Roche AG Commercial
    POLATUZUMAB VEDOTIN; RITUXIMAB
    2024-516904-40-00 8 countries 2018 n=356 Orphan
    Ended
  • Incyte Corp. Commercial
    TAFASITAMAB
    2022-500237-92-00 11 countries 2021 n=392 Orphan
    Ended
  • Merck Sharp & Dohme LLC Commercial
    ZILOVERTAMAB VEDOTIN
    2024-515566-13-00 11 countries 2025 n=258
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-508343-48-00 7 countries 2019 n=128
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    ODRONEXTAMAB
    2022-502783-21-00 10 countries 2024 n=132 Orphan
    Recruiting
  • Fondazione Italiana Linfomi Ets Academic
    IMP not specified
    2024-511637-35-00 1 country 2021 n=430
    Ended
  • Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic
    DEXRAZOXANE
    2023-505377-32-00 1 country 2024 n=324
    Recruiting
  • University Of Saarland Academic
    ACALABRUTINIB
    2022-501187-18-00 2 countries 2023 n=360
    Recruiting

Phase II

13 trials
  • ADC Therapeutics S.A. Commercial
    ADCT-402; RITUXIMAB
    2022-501601-12-00 2 countries 2023 n=28 Orphan
    Ended
  • F. Hoffmann-La Roche AG Commercial
    GLOFITAMAB; TOCILIZUMAB
    2023-504994-19-00 5 countries 2020 n=20
    Ended
  • Merck Sharp & Dohme LLC Commercial
    ZILOVERTAMAB VEDOTIN
    2024-515526-89-00 5 countries 2025 n=240
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    ODRONEXTAMAB
    2024-511747-25-00 5 countries 2019 n=225 Orphan
    Ended
  • Fondazione Italiana Linfomi Ets Academic
    GOLCADOMIDE
    2023-506206-38-00 1 country 2025 n=47
    Recruiting
  • Fondazione Italiana Linfomi Ets Academic
    IMP not specified
    2024-511641-18-00 1 country 2019 n=75
    Ended
  • Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic
    ATEZOLIZUMAB
    2022-501076-26-00 2 countries 2018 n=109
    Ended
  • Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic
    BRENTUXIMAB VEDOTIN
    2023-510556-22-00 3 countries 2018 n=36
    Ended
  • Instytut Hematologii I Transfuzjologii Academic
    AXICABTAGENE CILOLEUCEL; BENDAMUSTINE HYDROCHLORIDE; CISPLATIN; CYTARABINE; DEXAMETHASONE; LENALIDOMIDE; POLATUZUMAB VEDOTIN; RITUXIMAB; TAFASITAMAB
    2024-518275-64-00 1 country n=340 Orphan
    Pending
  • LYSARC Academic
    LENALIDOMIDE; PREDNISONE; RITUXIMAB; TAFASITAMAB; VINCRISTINE SULFATE
    2023-507286-25-00 2 countries 2021 n=45
    Ended
  • Universitaet Muenster Academic
    EPCORITAMAB; LONCASTUXIMAB TESIRINE
    2023-509861-19-00 1 country n=104 Orphan
    Not authorised
  • Universitaet Muenster Academic
    EPCORITAMAB; LONCASTUXIMAB TESIRINE
    2023-509861-19-01 1 country 2025 n=104 Orphan
    Recruiting
  • Universitaetsklinikum Muenster AöR Academic
    COPANLISIB DIHYDROCHLORIDE
    2024-517166-42-00 1 country 2020 n=61
    Ended

Phase I/II

3 trials
  • AstraZeneca AB Commercial
    ACALABRUTINIB; HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST CD3 AND CD19; SUROVATAMIG
    2024-515034-33-00 5 countries 2025 n=200
    Recruiting
  • Celgene Corp. Commercial
    GOLCADOMIDE; VALEMETOSTAT TOSILATE
    2024-515690-10-00 4 countries 2019 n=204 Orphan
    Recruiting
  • Incyte Corp. Commercial
    LENALIDOMIDE; TAFASITAMAB
    2023-507993-42-00 5 countries 2022 n=38 Orphan
    Ended

Phase IV

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IBRUTINIB
    2023-507329-40-00 7 countries 2017 n=125
    Ended

Phase I

10 trials
  • Exscientia AI Limited Commercial
    IMP not specified
    2024-516869-36-00 5 countries 2025 n=101
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-507497-40-00 3 countries 2021 n=36
    Ended
  • Incyte Corp. Commercial
    IMP not specified
    2022-501505-13-00 4 countries 2023 n=140
    Ended
  • Janssen - Cilag International Commercial
    IMP not specified
    2025-523297-16-00 2 countries 2026 n=37
    Recruiting
  • Miltenyi Biomedicine GmbH Commercial
    AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19
    2024-513334-38-00 1 country 2018 n=49
    Ended
  • Nurix Therapeutics Inc. Commercial
    IMP not specified
    2023-510541-25-00 5 countries 2023 n=250
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2022-502390-41-00 4 countries 2024 n=35
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-505813-26-00 5 countries 2024 n=48
    Ended
  • Regeneron Pharmaceuticals Inc. Academic
    IMP not specified
    2022-502137-26-00 3 countries 2024 n=42
    Halted
  • Technische Universitat Dresden Academic
    IMP not specified
    2022-502831-20-00 1 country 2024 n=16
    Recruiting

Phase I (Other)

2 trials
  • Celgene Corp. Commercial
    IMP not specified
    2022-501855-97-00 2 countries 2023 n=6
    Ended
  • Celgene Corp. Commercial
    IMP not specified
    2023-506094-35-00 3 countries 2021 n=112
    Ended

Phase I (First in Human)

4 trials
  • BeOne Medicines AG Commercial
    IMP not specified
    2022-502157-33-00 5 countries 2023 n=239
    Recruiting
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2023-507062-34-00 5 countries 2020 n=142
    Ended
  • Taiho Oncology Inc. Commercial
    TOLINAPANT LACTATE
    2024-516679-33-00 2 countries 2017 n=16
    Ended
  • Uppsala Universitet Academic
    IMP not specified
    2024-511844-18-00 1 country 2024 n=30
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
F. Hoffmann-La Roche AG Commercial 4 Phase I, Phase II, Phase III 0
Celgene Corp. Commercial 4 Phase I (Other), Phase III, Phase I/II 1
Incyte Corp. Commercial 3 Phase I, Phase III, Phase I/II 0
Regeneron Pharmaceuticals Inc. Commercial 3 Phase II, Phase III, Phase I 1
AbbVie Deutschland GmbH & Co. KG Commercial 3 Phase III, Phase IV 1
Fondazione Italiana Linfomi Ets Academic 3 Phase II, Phase III 1
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic 3 Phase II, Phase III 1
Seagen Inc. Commercial 2 Phase I 0
ADC Therapeutics S.A. Commercial 2 Phase II, Phase III 0
Merck Sharp & Dohme LLC Commercial 2 Phase II, Phase III 2
Novartis Pharma AG Commercial 2 Phase III, Phase I (First in Human) 0
Universitaet Muenster Academic 2 Phase II 1
Exscientia AI Limited Commercial 1 Phase I 1
Janssen - Cilag International Commercial 1 Phase I 1
Miltenyi Biomedicine GmbH Commercial 1 Phase I 0
Nurix Therapeutics Inc. Commercial 1 Phase I 1
Acerta Pharma B.V. Commercial 1 Phase III 0
BeOne Medicines AG Commercial 1 Phase I (First in Human) 1
Taiho Oncology Inc. Commercial 1 Phase I (First in Human) 0
AstraZeneca AB Commercial 1 Phase I/II 1
New trials by year
2019
4
2020
4
2021
6
2022
1
2023
8
2024
9
2025
6
2026
1
← All indication landscapes